

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/084799 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/IL2004/000279
- (22) International Filing Date: 25 March 2004 (25.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
155111 27 March 2003 (27.03.2003) IL
- (71) Applicant and
(72) Inventor: APPELBAUM, Jerachmiel [IL/IL]; 7 Ein Rogel St., IL-93543 Jerusalem (IL).

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: PHARMACEUTICAL COMPOSITIONS FOR INHIBITING METAL ION DEPENDENT ENZYMATIC ACTIVITY AND METHODS FOR THE USE THEREOF



(57) Abstract: The present invention provides pharmaceutical compositions for inhibiting pathological functions of metal-dependent metalloproteases as well as for neutralizing bacterial virulence factors by employing chelators of transition metals, resulting in reduction in the availability of such metals, or by replacing the key metal ions with different ions. In addition, a use of such metalloprotease inhibitors for the manufacture of a pharmaceutical composition for the prevention or treatment of pathological conditions influenced by the action of metalloproteases is disclosed. Also methods of treatment or prevention of such conditions are disclosed.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.